LXEO insider reports RSU release and tax-related share sales

Rhea-AI Filing Summary

Lexeo Therapeutics (LXEO) insider activity: the Chief Legal Officer reported acquiring 9,900 shares of common stock on 10/15/2025 at $0, and selling shares to cover tax obligations on released RSUs.

On 10/17/2025, the officer sold 3,486 shares at a weighted average price of $8.935 (trades ranged from $8.53 to $9.52) and 40 shares at a weighted average price of $9.561 (trades ranged from $9.53 to $9.59). Following these transactions, beneficial ownership was 68,930 shares, which includes 51,092 RSUs, with each RSU representing a right to one share.

Insights

Insider transactions analyst

Routine Form 4: RSU release and tax-related sales.

An executive of Lexeo Therapeutics reported typical equity events: 9,900 common shares acquired at $0 tied to RSU release, followed by sales to cover withholding taxes. Such transactions are common when restricted units vest.

The sales on 10/17/2025 were modest in size: 3,486 shares at a weighted average of $8.935 (range $8.53–$9.52) and 40 shares at $9.561 (range $9.53–$9.59). Post-trade holdings were 68,930 shares, including 51,092 RSUs. Actual market impact is typically limited for events of this scale.

Insider Trade Summary

Net Seller: 3,526 shares ($31,530)

Net Sell 3 txns

Insider Robertson Jenny

Role Chief Legal Officer

Sold 3,526 shs ($32K)

Type	Security	Shares	Price	Value
Sale	Common Stock	3,486	$8.935	$31K
Sale	Common Stock	40	$9.561	$382.44
Grant/Award	Common Stock	9,900	$0.00	--

Holdings After Transaction: Common Stock — 68,970 shares (Direct)

Footnotes (1)

1. Represents a sale to cover tax obligations on the release of Restricted Stock Units ("RSUs"). This transaction was executed in multiple trades at prices ranging from $8.53 to $9.52. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. This transaction was executed in multiple trades at prices ranging from $9.53 to $9.59. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Includes 51,092 RSUs. Each RSU represents a contingent right to receive one share of Common Stock of the Issuer.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Robertson Jenny

(Last) (First) (Middle)

C/O LEXEO THERAPEUTICS, INC.

345 PARK AVENUE SOUTH, FLOOR 6

(Street)

NEW YORK NY 10010

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Lexeo Therapeutics, Inc. [ LXEO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Legal Officer

3. Date of Earliest Transaction (Month/Day/Year)
10/15/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/15/2025		A		9,900	A	$0	72,456	D
Common Stock	10/17/2025		S(1)		3,486	D	$8.935(2)	68,970	D
Common Stock	10/17/2025		S(1)		40	D	$9.561(3)	68,930(4)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a sale to cover tax obligations on the release of Restricted Stock Units ("RSUs").

2. This transaction was executed in multiple trades at prices ranging from $8.53 to $9.52. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

3. This transaction was executed in multiple trades at prices ranging from $9.53 to $9.59. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

4. Includes 51,092 RSUs. Each RSU represents a contingent right to receive one share of Common Stock of the Issuer.

	/s/ Youjin Choi, Attorney-in-Fact	10/17/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did LXEO's Chief Legal Officer report on Form 4?

Acquisition of 9,900 common shares on 10/15/2025 and sales of shares on 10/17/2025 to cover tax obligations related to RSU release.

How many LXEO shares were sold and at what prices?

Sold 3,486 shares at a weighted average of $8.935 (range $8.53–$9.52) and 40 shares at $9.561 (range $9.53–$9.59) on 10/17/2025.

How many LXEO shares does the officer own after these transactions?

Beneficial ownership was 68,930 shares following the reported transactions.

Does the reported ownership include RSUs?

Yes. It includes 51,092 RSUs, each representing a right to receive one share of common stock.

What was the purpose of the LXEO share sales?

The filing states the sales were to cover tax obligations on the release of RSUs.

Were the trades executed as multiple fills?

Yes. The weighted average prices reflect multiple trades within the stated price ranges on 10/17/2025.